Adaptive Bio technologies, immune-driven medicine by harnessing the inherent biology, filed for an IPO with NASDAQ under the symbol “ADPT”.
Adaptive Bio technologies offering 12.5 million shares at a price range of $15.00 – $17.00.
Manager Goldman Sachs, Joint Managers J.P. Morgan and BofA Merrill Lynch. Cowen, Guggenheim Securities, William Blair, BTIG act as co-managers. The IPO is expected to price on June 27, 2019.
We are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient.
The IPO is expected to trade on NASDAQ on June 27, 2019
Featured photo credit to internet